Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-77242113 versus placebo and ustekinumab in moderate to severe plaque psoriasis
ISRCTN56487896Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra and ustekinumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoints: IGA 0/1 with at least 2-grade improvement from baseline at Week 16 and PASI 90 at Week 16. Started Apr 2025; status: active, not recruiting.
02
Drugs
icotrokinraustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ISRCTN56487896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56487896.